Article info

Download PDFPDF
Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate
  1. Correspondence to:
    Dr J Gratacós
    Rheumatology Unit, Parc Taulí University Hospital, Parc Taulí s/n. 08208 Sabadell, Barcelona, Spain; jgratacos{at}cspt.es
View Full Text

Citation

Gratacós J, Casado E, Real J, et al
Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate

Publication history

  • Accepted December 2, 2006
  • First published December 19, 2006.
Online issue publication 
March 14, 2007

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.